Get the Stockscreener App
4.04
8.02%
0.30
Prime Medicine Inc stock is traded at $4.04, with a volume of 4.71M.
It is up +8.02% in the last 24 hours and up +47.99% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$3.74
Open:
$3.51
24h Volume:
4.71M
Relative Volume:
1.30
Market Cap:
$543.36M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.8618
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
-4.04%
1M Performance:
+47.99%
6M Performance:
+44.29%
1Y Performance:
-22.16%
1-Day Range:
$3.51
$4.07
1-Week Range:
$3.51
$4.263
52-Week Range:
$1.11
$5.18
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.04 | 503.02M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Citigroup | Buy → Neutral |
| May-20-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-20-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Why is Prime Medicine Inc. stock attracting strong analyst attentionWealth Building Guidance For Smart Trading - jammulinksnews.com
Major Stakeholders Make Bold Moves in Prime Medicine Stock! - TipRanks
Arch venture fund XII buys Prime Medicine shares worth $9.99m - Investing.com
Prime Medicine's $144.2M Equity Raise and Strategic Implications - AInvest
Prime Medicine's Strategic Capital Raise: A Catalyst for Gene Editing Innovation and Shareholder Value - AInvest
Prime Medicine Announces Closing of Public Offering and - GlobeNewswire
Prime Medicine Secures $144M Funding Boost with Strategic Cystic Fibrosis Foundation Investment - Stock Titan
JonesTrading Maintains a Buy on Prime Medicine (PRME) - Insider Monkey
Cathie Wood’s ARK buys Prime Medicine, sells CRISPR stock By Investing.com - Investing.com India
Cathie Wood’s ARK buys Prime Medicine, sells CRISPR stock - Investing.com
Prime Medicine Announces $120.2M Public Stock Offering - TipRanks
Is it the right time to buy Prime Medicine Inc. stockBest Dividend Insights For Fast Growth - jammulinksnews.com
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
Prime Medicine stock falls after pricing public offering - Investing.com
Prime Medicine stock falls after pricing public offering By Investing.com - Investing.com South Africa
Why Did Prime Medicine Plunge 13.01%? Regulatory Setbacks, Partnership Concerns - AInvest
Prime Medicine's $125M Fundraise: A Strategic Inflection Point for Gene Editing Innovation - AInvest
Prime Medicine's $3.30 IPO: A High-Stakes Bet on Gene Editing's Future - AInvest
Prime Medicine Secures $125M Public Offering with Cystic Fibrosis Foundation Backing - Stock Titan
Prime Medicine Announces Pricing of Public Offering - GlobeNewswire Inc.
RSI Suggests Rebound May Be Near in Prime Medicine Inc.Step-by-Step Stock Investment Guide Gains Popularity - beatles.ru
Prime Medicine announces common stock offering, no amount given - TipRanks
Prime Medicine Halts Sales Agreement Prospectus - TipRanks
Prime Medicine falls on stock offering launch - TradingView
Prime Medicine launches public offering of common stock By Investing.com - Investing.com South Africa
Prime Medicine launches public offering of common stock - Investing.com Australia
Form 424B5 Prime Medicine, Inc. - StreetInsider
Prime Medicine Announces Proposed Public Offering of Common Stock - GlobeNewswire
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
What makes Prime Medicine Inc. stock price move sharplyCapital Protection Trading Strategies Gain Interest - metal.it
Is Prime Medicine Inc. the Top Chart Pick This WeekCapital Protection Trading Strategies Gain Interest - metal.it
Heatmap Data Shows High Activity in Prime Medicine Inc. SectorStock Portfolio Allocation Guidance for Volatile Markets - metal.it
Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid strategic shift By Investing.com - Investing.com South Africa
Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid strategic shift - Investing.com
Intraday Charts Show Spike in Prime Medicine Inc. ActivityShort Term High Yield Stock Tips for Active Traders - metal.it
What are the technical indicators suggesting about Prime Medicine Inc.Free Stock Trend Scanner That Work - jammulinksnews.com
What is Prime Medicine Inc. company’s growth strategyConsistent double returns - jammulinksnews.com
When is Prime Medicine Inc. stock expected to show significant growthBreakthrough investment results - jammulinksnews.com
How many analysts rate Prime Medicine Inc. as a “Buy”Free Investment Portfolio Suggestions - jammulinksnews.com
What are Prime Medicine Inc. company’s key revenue driversHigh-impact stock picks - jammulinksnews.com
What is the risk reward ratio of investing in Prime Medicine Inc. stockOutperformance with explosive growth - jammulinksnews.com
What institutional investors are buying Prime Medicine Inc. stockAchieve consistent profits with smart trading - jammulinksnews.com
Does Prime Medicine Inc. stock perform well during market downturnsExplosive earnings growth - jammulinksnews.com
What are the latest earnings results for Prime Medicine Inc.Get high-impact stock recommendations now - jammulinksnews.com
How Prime Medicine Inc. stock performs during market volatilitySmart Return Focused Trading - metal.it
What drives Prime Medicine Inc. stock priceUnmatched market performance - PrintWeekIndia
Is Prime Medicine Inc. a good long term investmentFree Capital Growth Strategies - Autocar Professional
Is Prime Medicine Inc. stock a good hedge against inflationFree Risk Assessment Services - jammulinksnews.com
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prime Medicine Inc Stock (PRME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):